Soligenix, Inc. (SNGX)

NASDAQ: SNGX · IEX Real-Time Price · USD
7.43
-0.22 (-2.88%)
At close: Jul 12, 2024, 4:00 PM
7.35
-0.08 (-1.08%)
After-hours: Jul 12, 2024, 7:58 PM EDT
-2.88%
Market Cap 7.34M
Revenue (ttm) 699,210
Net Income (ttm) -7.01M
Shares Out 987.49K
EPS (ttm) -11.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,313,080
Open 7.26
Previous Close 7.65
Day's Range 7.10 - 8.25
52-Week Range 1.83 - 32.00
Beta 1.87
Analysts n/a
Price Target n/a
Earnings Date Aug 19, 2024

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inf... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 1987
Employees 13
Stock Exchange NASDAQ
Ticker Symbol SNGX
Full Company Profile

Financial Performance

In 2023, Soligenix's revenue was $839,359, a decrease of -11.55% compared to the previous year's $948,911. Losses were -$6.14 million, -55.50% less than in 2022.

Financial Statements

News

Soligenix stock rallies 400% on positive HyBryte trial results

Soligenix Inc (NASDAQ: SGNX) reported positive interim data from a trial of its HyBryte therapy on Tuesday.  HyBryte is the biopharmaceutical firm's treatment for early-stage cutaneous T-cell lymphoma...

5 days ago - Invezz

Crude Oil Down 1%; Soligenix Shares Surge

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday.

5 days ago - Benzinga

Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Soligenix Inc SNGX shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro.

5 days ago - Benzinga

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmace...

5 days ago - PRNewsWire

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Sol...

19 days ago - PRNewsWire

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (...

4 weeks ago - PRNewsWire

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show...

Other symbols: STSS
5 weeks ago - Accesswire

Soligenix Announces Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmac...

6 weeks ago - PRNewsWire

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bi...

6 weeks ago - PRNewsWire

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

7 weeks ago - PRNewsWire

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company fo...

7 weeks ago - PRNewsWire

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

PRINCETON, N.J. , May 21, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

7 weeks ago - PRNewsWire

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

Annual Meeting to be held May 23, 2024 PRINCETON, N.J., May 20, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo...

7 weeks ago - PRNewsWire

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bi...

2 months ago - PRNewsWire

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

PRINCETON, N.J. , May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

2 months ago - PRNewsWire

Soligenix to Present at Upcoming Conferences

PRINCETON, N.J. , May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

2 months ago - PRNewsWire

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Includes thermostabilized Ebola vaccines MarVax™ and SuVax™ Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON, N.J. , April 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX...

2 months ago - PRNewsWire

Soligenix Announces Pricing of $4.75 Million Public Offering

PRINCETON, N.J. , April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing product...

3 months ago - PRNewsWire

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval  PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company...

3 months ago - PRNewsWire

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Provides SuVax™   Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company...

3 months ago - PRNewsWire

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study PRINCETON, N.J. , April 3, 2024 /PRNewswire/ -- Sol...

3 months ago - PRNewsWire

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

PRINCETON, N.J. , March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...

4 months ago - PRNewsWire

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J. , Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharm...

5 months ago - PRNewsWire

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, ...

Other symbols: MOB
6 months ago - Accesswire

Soligenix to Present at The Microcap Conference

PRINCETON, N.J. , Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

6 months ago - PRNewsWire